Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties, today announced that it will strengthen its collaboration in the fill- finish of the COVID-19 Vaccine Moderna by increasing its fill-finish capacity. To this end, further industrial investments will be made in the ROVI Group’s facility in Madrid (Spain).

These investments consist of the installation of two new production lines and equipment for compounding, filling, automatic visual inspection, labelling and packaging that will provide additional fill-finish capacity for the COVID-19 Vaccine Moderna, intended to supply markets outside the United States. These lines, located at ROVI’s facility in San Sebastián de los Reyes (Madrid), will come into operation in the fourth quarter of 2021 and be fully operational in the first half of 2022 and will more than double the number of vials for which there is fill-finish capacity at this facility.

Juan López-Belmonte Encina, ROVI’s Chief Executive Officer, said, “We are delighted at our collaboration with Moderna, whose vaccine against COVID-19 is well positioned in the race to try to solve this health crisis. The expansion of our fill and finish capacity will allow us to increase our contribution to solving this pandemic that is affecting everyone. We are confident that our proven experience and capacities as a contract manufacturer of injectables with high technological value will enable us to provide”